Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD

Prim Care Respir J. 2008 Sep;17(3):169-75. doi: 10.3132/pcrj.2008.00037.


Aims: Evaluation of tiotropium efficacy in patients with mild chronic obstructive pulmonary disease (COPD) defined by the 2003 Swedish Society of Respiratory Medicine guidelines (post-bronchodilator FEV1/FVC <70%; FEV1 >60% predicted).

Methods: In this 12-week, randomised, double-blind, placebo-controlled study of tiotropium 18 mcg once daily versus placebo, respiratory function was assessed on Days 1, 15 and 85 (baseline: pre-dose Day 1).

Results: Mean+/-SD baseline FEV1 (% predicted) was 73.4+/-12.5 (tiotropium, n=107; placebo, n=117). Tiotropium significantly improved change from baseline in area under the curve from pre-dose to 2 hours post-dose (AUC0-2 h) FEV1 versus placebo, by 166+/-26 mL (mean+/-SE) at study end (p<0.0001). With tiotropium, there were significant increases in the change in AUC0-2 h FVC versus baseline, and trough FEV1 and FVC, versus placebo, on all test days (p<0.01). Adverse event rates were similar.

Conclusion: Compared with placebo, tiotropium improved lung function in patients with mild COPD.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchodilator Agents / therapeutic use*
  • Double-Blind Method
  • Dyspnea / drug therapy
  • Dyspnea / etiology
  • Female
  • Forced Expiratory Volume / drug effects
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Quality of Life
  • Scopolamine Derivatives / therapeutic use*
  • Severity of Illness Index
  • Spirometry
  • Tiotropium Bromide
  • Vital Capacity / drug effects


  • Bronchodilator Agents
  • Scopolamine Derivatives
  • Tiotropium Bromide